This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Oct;9(10):550.

doi: 10.1038/nrclinonc.2012.151. Epub 2012 Aug 21.

Glioblastoma: Will you still fit me when I'm seventy-four?

M Teresa Villanueva

PMID: 22910683
DOI: 10.1038/nrclinonc.2012.151

Comment

Glioblastoma: Will you still fit me when I'm seventy-four?

M Teresa Villanueva. Nat Rev Clin Oncol. 2012 Oct.

. 2012 Oct;9(10):550.

doi: 10.1038/nrclinonc.2012.151. Epub 2012 Aug 21.

Author

M Teresa Villanueva

PMID: 22910683
DOI: 10.1038/nrclinonc.2012.151

No abstract available

PubMed Disclaimer

Comment on

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG). Malmström A, et al. Lancet Oncol. 2012 Sep;13(9):916-26. doi: 10.1016/S1470-2045(12)70265-6. Epub 2012 Aug 8. Lancet Oncol. 2012. PMID: 22877848 Clinical Trial.

References

1. Lancet Oncol. 2012 Sep;13(9):916-26 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.